On May 10, accompanied by Qiao Shibo, Fu Yuning visited the headquarters of CR Pharmaceuticals in Beijing and held a forum with the management team.

Heads of CR Pharmaceuticals reported on the current business status, the management and control mode, strategic development targets, etc., and outlined the challenges and opportunities the CR Medical is faced with in reference to the policies, characteristics, industrial risks and market competition of the medical industry, as well as the focuses of reform, innovation and development. Heads of the three listed companies, CR Sanjiu, CR Double-Crane and Donge Ejiao reported on the production and operations of their own companies.

Fu expressed his satisfaction with the achievements of CR Pharmaceuticals in the increasingly fierce competition of the industry, with its leading status steadily rising in the industry and his hope that it will continue to play a key role in the attainment of the overall growth targets of the whole Group. According to Fu, CR Pharmaceuticals has many advantages: The first is its network, which will help increase and retain its market share on a long-term basis and bring more opportunities to cooperate with its strategic partners. The second is its brand image and a broad range of product lines with strong industrial features. Its business practices in the distribution sector have also laid a solid foundation for its future development. CR Pharmaceuticals should make the best use of those advantages for the sake of a better future. Fu pointed out that the population growth and the aging trend have dictated the prospects of the pharmaceutical market with great potentials and the development of the pharmaceutical industry is in line with the strategic direction of the Group. He hoped that the management team of CR Pharmaceuticals will continue to build and maintain its brand image and increase its public influence.

After the forum, Fu and Qiao talked with employees of CR Pharmaceuticals and encouraged them to work hard to attain mutual development and progress with CR.